WallStreetZenWallStreetZen

NASDAQ: BRNS
Barinthus Biotherapeutics PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BRNS

Based on 1 analyst offering 12 month price targets for Barinthus Biotherapeutics PLC

Min Forecast
$4.00+406.33%
Avg Forecast
$4.00+406.33%
Max Forecast
$4.00+406.33%

Should I buy or sell BRNS stock?

Based on 1 analyst offering ratings for Barinthus Biotherapeutics PLC.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BRNS stock forecasts and price targets.

BRNS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-17

1 of 1

Forecast return on equity

Is BRNS forecast to generate an efficient return?

Company
-71.99%
Industry
90.54%
Market
341.05%
BRNS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BRNS forecast to generate an efficient return on assets?

Company
-55.68%
Industry
23.8%
BRNS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BRNS earnings per share forecast

What is BRNS's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.90
Avg 2 year Forecast
-$1.46
Avg 3 year Forecast
-$1.49

BRNS revenue forecast

What is BRNS's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

BRNS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BRNS$0.79$4.00+406.33%Buy
RADX$4.56$15.50+239.91%Strong Buy
QNRX$21.75N/AN/A
PTN$19.54N/AN/A
RNXT$0.92$12.50+1,263.14%Buy
View Top Biotech Stocks

Barinthus Biotherapeutics Stock Forecast FAQ

Is Barinthus Biotherapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BRNS) stock is to Buy BRNS stock.

Out of 1 analyst, 0 (0%) are recommending BRNS as a Strong Buy, 1 (100%) are recommending BRNS as a Buy, 0 (0%) are recommending BRNS as a Hold, 0 (0%) are recommending BRNS as a Sell, and 0 (0%) are recommending BRNS as a Strong Sell.

If you're new to stock investing, here's how to buy Barinthus Biotherapeutics stock.

What is BRNS's earnings growth forecast for 2025-2027?

(NASDAQ: BRNS) Barinthus Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 73.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 104.66%.

Barinthus Biotherapeutics's earnings in 2025 is -$75,878,000.On average, 4 Wall Street analysts forecast BRNS's earnings for 2025 to be -$77,463,346, with the lowest BRNS earnings forecast at -$74,425,567, and the highest BRNS earnings forecast at -$79,741,679. On average, 4 Wall Street analysts forecast BRNS's earnings for 2026 to be -$59,555,153, with the lowest BRNS earnings forecast at -$57,219,657, and the highest BRNS earnings forecast at -$61,306,775.

In 2027, BRNS is forecast to generate -$60,804,562 in earnings, with the lowest earnings forecast at -$58,420,069 and the highest earnings forecast at -$62,592,931.

What is BRNS's revenue growth forecast for 2025-2027?

(NASDAQ: BRNS) Barinthus Biotherapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 282.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.02%.

Barinthus Biotherapeutics's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast BRNS's revenue for 2025 to be $0, with the lowest BRNS revenue forecast at $0, and the highest BRNS revenue forecast at $0. On average, 4 Wall Street analysts forecast BRNS's revenue for 2026 to be $0, with the lowest BRNS revenue forecast at $0, and the highest BRNS revenue forecast at $0.

In 2027, BRNS is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is BRNS's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: BRNS) forecast ROA is -55.68%, which is lower than the forecast US Biotechnology industry average of 23.8%.

What is BRNS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BRNS price target, the average BRNS price target is $4.00, with the highest BRNS stock price forecast at $4.00 and the lowest BRNS stock price forecast at $4.00.

The Wall Street analyst predicted that Barinthus Biotherapeutics's share price could reach $4.00 by Nov 17, 2026. The average Barinthus Biotherapeutics stock price prediction forecasts a potential upside of 406.33% from the current BRNS share price of $0.79.

What is BRNS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BRNS) Barinthus Biotherapeutics's current Earnings Per Share (EPS) is -$1.88. On average, analysts forecast that BRNS's EPS will be -$1.90 for 2025, with the lowest EPS forecast at -$1.82, and the highest EPS forecast at -$1.95. On average, analysts forecast that BRNS's EPS will be -$1.46 for 2026, with the lowest EPS forecast at -$1.40, and the highest EPS forecast at -$1.50. In 2027, BRNS's EPS is forecast to hit -$1.49 (min: -$1.43, max: -$1.53).

What is BRNS's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: BRNS) forecast ROE is -71.99%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.